Zinc antagonizes homocysteine-induced fetal heart defects in rats

Cardiovascular Toxicology

Volumn 9, Issue 3, 2009, Pages 151-159

  He, Xiaoyu ^a   Hong, Xinru ^a   Zeng, Fang ^a   Kang, Fenhong ^a   Li, Li ^a   Sun, Qinghua ^b,c  

^a FUZHOU GENERAL HOSPITAL   (China)

^b OHIO STATE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

Fetus; Heart defects; Homocysteine; Oxidative stress; Rat; Zinc

Indexed keywords

BIOLOGICAL MARKER; COPPER ZINC SUPEROXIDE DISMUTASE; FOLIC ACID; HOMOCYSTEINE; MESSENGER RNA; METALLOTHIONEIN I; ZINC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONGENITAL HEART MALFORMATION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; FEMALE; FETUS; FETUS DEVELOPMENT; FETUS HEART; FETUS RESORPTION; GENE EXPRESSION; GESTATIONAL AGE; NONHUMAN; OXIDATIVE STRESS; PEROXIDATION; PRIORITY JOURNAL; RAT; SPRAGUE DAWLEY RAT; TERATOGENICITY; ANIMAL; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; CONGENITAL MALFORMATION; PREGNANCY;

RATTUS;

ANIMALS; FEMALE; FETAL HEART; HEART DEFECTS, CONGENITAL; HOMOCYSTEINE; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; ZINC;

EID: 77950958368     PISSN: 15307905     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12012-009-9048-0     Document Type: Article

References (28)

1. Bentham, J., & Bhattacharya, S. (2008). Genetic mechanisms controlling cardiovascular development. Annals of the New York Academy of Sciences, 1123, 10-19.
2. Tennstedt, C., Chaoui, R., Korner, H., & Dietel, M. (1999). Spectrum of congenital heart defects and extracardiac malformations associated with chromosomal abnormalities: Results of a seven year necropsy study. Heart, 82, 34-39.
3. Botto, L. D., & Correa, A. (2003). Decreasing the burden of congenital heart anomalies: An epidemiologic evaluation of risk factors and survival. Progress in Pediatric Cardiology, 18, 111-121.
4. Verkleij-Hagoort, A. C., Verlinde, M., Ursem, N. T., Lindemans, J., Helbing, W. A., Ottenkamp, J., et al. (2006). Maternal hyperhomocysteinaemia is a risk factor for congenital heart disease. BJOG, 113, 1412-1418.
5. Beksac, M. S., Balci, S., Guvendag-Guven, E. S., Guven, S., & Ozkutlu, S. (2007). Complex conotruncal cardiac anomalies consecutively in three siblings from a consanguineous family possibly associated with maternal hyperhomocysteinemia. Archives of Gynecology and Obstetrics, 276, 547-549.
6. van Beynum, I. M., Kouwenberg, M., Kapusta, L., & den Heijer, M. (2006). MTRR 66A[G polymorphism in relation to congenital heart defects. Clinical Chemistry and Laboratory Medicine, 44, 1317-1323.
7. Taparia, S., van Waes, G. J., Rosenquist, T. H., & Finnell, R. H. (2007). Importance of folate-homocysteine homeostasis during early embryonic development. Clinical Chemistry and Laboratory Medicine, 45, 1717-1727.
8. Moens, L., Vrints, C. J., Claeys, M. J., Timmermans, J. P., Champion, H. C., & Kass, D. A. (2008). Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease. American Journal of Physiology. Heart and Circulatory Physiology, 294, H1971-H1977.
9. Botto, L. D., Mulinare, J., & Erickson, J. D. (2000). Occurrence of congenital heart defects in relation to maternal multivitamin use. American Journal of Epidemiology, 151, 878-884.
10. Arbour, L., Rupps, R., MacDonald, S., Forth, M., Yang, J., Nowdluk, M., et al. (2006). Congenital heart defects in Canadian Inuit: Is more folic acid making a difference? Alaska Medicine, 49(Suppl. 2), 163-166.
11. Formigari, A., Irato, P., & Santon, A. (2007). Zinc, antioxidant systems and metallothionein in metal mediated-apoptosis: Biochemical and cytochemical aspects. Comparative Biochemistry and Physiology. Toxicology & Pharmacology, 146, 443-459.
12. Hobbs, C. A., Malik, S., Zhao, W., James, S. J., Melnyk, S., & Cleves, M. A. (2006). Maternal homocysteine and congenital heart defects. American College of Cardiology Journal, 47, 683-685.
13. L'abbe, M. R., & Fischer, P. W. (1986). An automated method for the determination of Cu, Zn-superoxide dismutase in plasma and erythrocytes using an ABA-200 discrete analyzer. Clinical Biochemistry, 19, 175-178.
14. Hobbs, C. A., Cleves, M. A., Melnyk, S., Zhao, W., & James, S. J. (2005). Congenital heart defects and abnormal maternal biomarkers of methionine and homocysteine metabolism. American Journal of Clinical Nutrition, 81, 147-153.
15. Elmore, C. L., Wu, X., Leclerc, D., Watson, E. D., Bottiglieri, T., Krupenko, N. I., et al. (2007). Metabolic derangement of methionine and folate metabolism in mice deficient in methionine synthase reductase. Molecular Genetics and Metabolism, 91, 85-97.
16. Powell, S. R. (2000). The antioxidant properties of zinc. The Journal of Nutrition, 130(Suppl. 5), 1447S-1454S.
17. Rokicki, W., Strzalkowski, A., Klapcinska, B., Danch, A., & Sobczak, A. (2003). Antioxidant status in newborns and infants suffering from congenital heart defects. Wiadomosci Lekarskie, 56, 337-340.
18. Hobbs, C. A., Cleves, M. A., Zhao, W., Melnyk, S., & James, S. J. (2005). Congenital heart defects and maternal biomarkers of oxidative stress. American Journal of Clinical Nutrition, 82, 598-604.
19. Merialdi, M., Caulfield, L. E., Zavaleta, N., Figueroa, A., Costigan, K. A., Dominici, F., et al. (2004). Randomized controlled trial of prenatal zinc supplementation and fetal bone growth. American Journal of Clinical Nutrition, 79, 826-830. (Pubitemid 41103883)
20. Duzguner, V., & Kaya, S. (2007). Effect of zinc on the lipid peroxidation and the antioxidant defense systems of the alloxaninduced diabetic rabbits. Free Radical Biology and Medicine, 42, 1481-1486.
21. King, J. C. (2000). Determinants of maternal zinc status during pregnancy. American Journal of Clinical Nutrition, 71(Suppl. 1), 1334S-1343S.
22. Song, Y., Wang, J., Li, X. K., & Cai, L. (2005). Zinc and the diabetic heart. BioMetals, 18, 325-332.
23. Thomas, M., Vidal, A., Bhattacharya, S. K., Ahokas, R. A., Sun, Y., Gerling, I. C., et al. (2007). Zinc dyshomeostasis in rats with aldosteronism. Response to spironolactone. American Journal of Physiology. Heart and Circulatory Physiology, 293, H2361-H2366.
24. Xu, L. J., Jin, L., Pan, H., Zhang, A. Z., Wei, G., Li, P. P., et al. (2006). Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin. Acta Pharmacologica Sinica, 27, 1333-1339.
25. Williams, A. S., Issa, R., Leung, S. Y., Nath, P., Ferguson, G. D., Bennett, B. L., et al. (2007). Attenuation of ozone-induced airway inflammation and hyper-responsiveness by c-Jun NH2 terminal kinase inhibitor SP600125. Journal of Pharmacology and Experimental Therapeutics, 322, 351-359.
26. Galdieri, L. C., Arrieta, S. R., Silva, C. M., Pedra, C. A., & D'Almeida, V. (2007). Homocysteine concentrations and molecular analysis in patients with congenital heart defects. Archives of Medical Research, 38, 212-218.
27. Huhta, J. C., & Hernandez, R. J. A. (2005). Homocysteine, folate, and congenital heart defects. Fetal and Pediatric Pathology, 24, 71-79.
28. Piao, F., Yokoyama, K., Ma, N., & Yamauchi, T. (2003). Subacute toxic effects of zinc on various tissues and organs of rats. Toxicology Letters, 145, 28-35.